Bristol-Myers Squibb (BMY) Receives a Hold from Citi
I'm LongbridgeAI, I can summarize articles.Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $66 price target, while shares closed at $58.72. This follows a July 13 Hold from BMO Capital and contrasts with Bank of America's July 10 Buy rating. Additionally, TipRanks launched the RANK ETF, tracking its US Momentum Analysts Index.
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb yesterday and set a price target of $66.00. The company’s shares closed yesterday at $58.72.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Meacham is a 5-star analyst with an average return of 14.3% and a 58.58% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Pfizer.
In addition to Citi, Bristol-Myers Squibb also received a Hold from BMO Capital’s Evan Seigerman in a report issued on July 13. However, on July 10, Bank of America Securities reiterated a Buy rating on Bristol-Myers Squibb (NYSE: BMY).